AIDA, Axin interactor, dorsalization-associated protein, is a crucial component in the intricate regulation of the Wnt/β-catenin signaling pathway, which holds sway over numerous cellular processes, including embryonic development, tissue homeostasis, and stem cell renewal. As a scaffold protein, AIDA facilitates the assembly of the β-catenin destruction complex, comprising Axin, APC, GSK3β, and CK1, orchestrating the phosphorylation and subsequent degradation of β-catenin. This regulatory mechanism serves to curtail aberrant activation of Wnt signaling by sequestering cytoplasmic β-catenin and impeding its translocation into the nucleus, where it acts as a transcriptional co-activator. By modulating the availability of β-catenin for nuclear translocation, AIDA effectively governs the expression of Wnt target genes involved in cell fate determination, proliferation, and differentiation, thereby exerting precise control over cellular responses to extracellular stimuli.
Inhibition of AIDA function disrupts the delicate balance maintained within the Wnt/β-catenin pathway, resulting in dysregulated cellular behavior and aberrant developmental processes. Various inhibitors targeting key components of signaling pathways upstream of AIDA-mediated Wnt regulation have been identified. These inhibitors predominantly act on molecules within the PI3K/Akt pathway, such as PI3K, Akt, and downstream effectors, effectively perturbing the signaling cascade that converges on AIDA modulation. By impeding the activity of PI3K and Akt, for instance, these inhibitors indirectly suppress AIDA expression and activity, thus abrogating its inhibitory effect on Wnt signaling. This indirect mode of inhibition underscores the interconnectedness of cellular signaling networks and highlights the potential for targeted intervention to modulate AIDA function and, consequently, Wnt pathway dynamics.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting PI3K/Akt signaling pathway, leading to down-regulation of AIDA expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Irreversible PI3K inhibitor hindering PI3K/Akt signaling pathway, resulting in suppression of AIDA activity. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
Akt inhibitor impeding Akt phosphorylation, thereby inhibiting downstream targets including AIDA. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $173.00 $230.00 $275.00 $332.00 | 9 | |
Pan-class I PI3K inhibitor reducing PI3K activity, consequently suppressing AIDA expression. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
PI3K inhibitor targeting multiple isoforms of PI3K, leading to inhibition of PI3K/Akt signaling and AIDA. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $184.00 $321.00 | 1 | |
Akt inhibitor interfering with Akt phosphorylation, ultimately inhibiting downstream targets such as AIDA. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $189.00 | 4 | |
Selective PI3Kδ inhibitor disrupting PI3K/Akt signaling, resulting in down-regulation of AIDA expression. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
Dual PI3K/mTOR inhibitor impeding PI3K/Akt/mTOR signaling cascade, leading to suppression of AIDA activity. | ||||||
GSK 1059615 | 958852-01-2 | sc-361198 sc-361198A | 10 mg 50 mg | $179.00 $825.00 | ||
PDK1 inhibitor disrupting PDK1/Akt pathway, thereby inhibiting phosphorylation and activation of AIDA. | ||||||
A-674563 | 552325-73-2 | sc-364393 sc-364393A | 2 mg 5 mg | $232.00 $413.00 | ||
Akt inhibitor targeting Akt phosphorylation, consequently inhibiting downstream signaling including AIDA. |